Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024

Zinger Key Points
  • GoodRx's guidance includes ongoing full-year effect of the Change Healthcare outage with its expected low-single-digit million-dollar impact
  • The 2024 growth rate has been tempered by the impact associated with the de-prioritization of vitaCare and the sunset of Kroger Savings Club

Thursday, GoodRx Holdings GDRX reported a first-quarter adjusted EPS of $0.08, which was in line with the consensus and higher than the $0.07 reported a year ago.

The company reported sales of $197.88 million, beating the consensus of $196.08 million.

Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million. 

Prescription transactions revenue increased 8% to $145.4 million, primarily driven by a 10% increase in Monthly Active Consumers, principally from organic growth. 

Subscription revenue decreased 6% to $22.6 million, primarily driven by a decrease in subscription plans due to the anticipated sunset of the partnership subscription program, Kroger Savings Club. 

Pharma manufacturer solutions revenue increased 20% to $24.5 million, primarily driven by organic growth. 

Related: GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings.

Guidance: GoodRx forecasts second-quarter revenue of ~$200 million versus consensus of $199.68 million, with adjusted EBITDA margin expected in the low thirty-percent range.

GoodRx expects 2024 revenue of $800 million-$810 million (prior view ~$800 million) versus a consensus of $800.99 million, with adjusted EBITDA over $250 million (prior view ~$250 million).

The full-year growth rate has been tempered by approximately $15 million of topline impact associated with the de-prioritization of vitaCare and the anticipated sunset of the Kroger Savings Club. 

Additionally, contra-revenue related to consumer incentives is expected to increase by almost $10 million this year. 

In aggregate, this anticipated $25 million topline impact is absorbed in 2024 sales guidance, as is the ongoing full-year effect of the Change Healthcare outage with its expected low-single-digit million-dollar impact.

Read Next: Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says.

Price Action: GDRX shares are down 8.74% at $6.945 at last check Thursday.

Photo: Song_about_summer/Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!